Elanco(US:ELAN)2025-11-05 13:00Financial Performance - Q3 2025 revenue reached $1.137 billion, a 10% increase compared to $1.030 billion in Q3 2024[32] - Organic constant currency (CC) revenue growth was 9%, driven by a 20% increase in U S Farm Animal and a 9% increase in U S Pet Health[9, 12] - Adjusted EBITDA for Q3 2025 was $198 million, up 21% from $163 million in Q3 2024[34] - Adjusted earnings per share (EPS) increased by 46% to $0 19, compared to $0 13 in Q3 2024[34] Innovation and Portfolio - Year-to-date (YTD) innovation revenue contribution was $655 million, with the 2025 target raised to $840-$880 million[9, 15] - Innovation sales target raised to deliver an incremental $840-$880 million, compared to $275 million in 2024[14, 15] Financial Guidance and Outlook - The company is increasing expected organic CC revenue growth to 6%-6 5%, with adjusted EBITDA of $880-$900 million and adjusted EPS of $0 91-$0 94 for 2025[10] - Full year revenue guidance is $4 645 - $4 670 billion, expecting 6%-6 5% organic CC growth[54] - The company expects an end-of-year net leverage ratio of 3 7x-3 8x[9, 41] Debt and Capital Allocation - Net debt decreased by $153 million in Q3 2025[41] - Refinanced $2 1 billion Term Loan B, extending maturity and lowering the cost of debt[9, 51]